Table 1.
Baseline demographics of participants with two equilibrium radionuclide angiocardiographic scans
| Control (n = 9) | Treatment Intensification (n = 10) | |
|---|---|---|
| Age, yr | 48 (29–77) | 48 (29–77) |
| Sex | ||
| Female | 5 (56%) | 6 (60%) |
| PAH | ||
| Idiopathic | 4 (44%) | 4 (40%) |
| Associated | 4 (44%) | 5 (50%) |
| Familial | 1 (11%) | 1 (10%) |
| Baseline therapies | ||
| None | 0 | 6 (60%) |
| Amb + Tad | 3 (33%) | 3 (30%) |
| (Amb + Tad) + treprostinil | ||
| Oral | 0 | 1 (10%) |
| Inhaled | 1 (11%) | 0 |
| Subcutaneous | 5 (56%) | 0 |
| Therapies added | ||
| None | 9 (100%) | 0 |
| Amb | 0 | 1 (10%) |
| Amb + Tad | 0 | 6 (60%) |
| Treprostinil | ||
| Oral | 0 | 2 (20%) |
| Subcutaneous | 0 | 2 (20%) |
| Functional class | ||
| Baseline | ||
| II/III | 8/1 | 10/0 |
| Follow-up | ||
| II/III | 8/1 | 10/0 |
| 6MWT | ||
| Baseline, m | 398 (305–659) | 459 (233–664) |
| Follow-up, m | 418 (278–638) | 461 (314–675) |
| NT-proBNP | ||
| Baseline | 202 (50–1,130) | 470 (50–4,367) |
| Follow-up | 173 (50–2,472) | 302 (50–1,298) |
Definition of abbreviations: 6MWT = 6-minute-walk test; Amb = ambrisentan; Tad = tadalafil; NT-proBNP = N-terminal prohormone brain natriuretic peptide; PAH = pulmonary arterial hypertension.
Age is median (range); the remainder of the numbers in parentheses until 6MWT are percentages. For the 6MWT and NT-proBNP, these are medians (range). NT-proBNP is pg/ml.